PriceTargets.com logo

Bionano Genomics - BNGO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.50
  • Forecasted Upside: 247.59%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.87 As of 02/3/2023 10:03 PM ET
▼ -0.1 (-5.08%)

This chart shows the closing price for BNGO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bionano Genomics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BNGO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BNGO

Analyst Price Target is $6.50
▲ +247.59% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Bionano Genomics in the last 3 months. The average price target is $6.50, with a high forecast of $12.00 and a low forecast of $3.50. The average price target represents a 247.59% upside from the last price of $1.87.

This chart shows the closing price for BNGO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Bionano Genomics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/13/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/11/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/12/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/8/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/7/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/4/2023ScotiabankInitiated CoverageSector Outperform$4.00Low
12/12/2022BTIG ResearchReiterated RatingBuy$3.50Low
7/18/2022OppenheimerReiterated RatingOutperform$12.00Low
4/7/2022BTIG ResearchLower TargetBuy$10.00 ➝ $7.00High
12/30/2021OppenheimerReiterated RatingOutperform ➝ Outperform$14.00Medium
11/5/2021Maxim GroupInitiated CoverageBuy$12.00Low
6/16/2021BTIG ResearchInitiated CoverageBuy$10.00High
3/24/2021OppenheimerReiterated RatingBuyHigh
2/8/2021OppenheimerBoost Target$1.50 ➝ $15.00Low
1/22/2021Maxim GroupBoost Target$2.00 ➝ $14.00High
12/4/2020Roth CapitalDowngradeBuy ➝ NeutralLow
9/24/2020LADENBURG THALM/SH SHInitiated CoverageBuy$1.25Medium
8/24/2020OppenheimerReiterated RatingBuyHigh
8/17/2020Maxim GroupInitiated CoverageBuy$2.00Medium
7/24/2020Maxim GroupReiterated RatingBuy$2.00High
7/17/2020Maxim GroupReiterated RatingBuy$2.00High
7/10/2020Maxim GroupInitiated CoverageBuy$2.00High
6/11/2020OppenheimerReiterated RatingBuy$1.50Medium
6/4/2020Roth CapitalReiterated RatingBuy$1.00High
4/19/2020OppenheimerInitiated CoverageOutperform$1.50Medium
4/8/2020OppenheimerInitiated CoverageOutperform$1.50High
4/1/2020Roth CapitalReiterated RatingBuyLow
4/1/2020Maxim GroupReiterated RatingBuy$3.00High
3/11/2020Maxim GroupReiterated RatingBuy$3.00High
12/6/2019Maxim GroupReiterated RatingBuy$3.00High
11/8/2019Maxim GroupReiterated RatingBuy$3.00Low
8/9/2019Maxim GroupReiterated RatingBuy$7.00Medium
7/31/2019Maxim GroupSet TargetBuy$7.00N/A
6/20/2019Maxim GroupReiterated RatingBuy$11.00Low
5/10/2019Maxim GroupReiterated RatingBuyHigh
4/1/2019Maxim GroupReiterated RatingBuy$11.00Low
3/18/2019Maxim GroupReiterated RatingBuyLow
3/6/2019Maxim GroupUpgradeBuy$11.00High
2/5/2019Roth CapitalReiterated RatingBuyLow
9/26/2018Roth CapitalInitiated CoverageBuy$12.00Medium
9/25/2018Maxim GroupInitiated CoverageBuyHigh
(Data available from 2/6/2018 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/11/2022
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
8/10/2022
  • 5 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/9/2022
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
10/9/2022
  • 9 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/8/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
12/8/2022
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
1/7/2023
  • 6 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
Mentions as of
2/6/2023

Current Sentiment

  • 6 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Bionano Genomics logo
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $1.87
Low: $1.86
High: $1.97

50 Day Range

MA: $1.79
Low: $1.40
High: $2.21

52 Week Range

Now: $1.87
Low: $1.16
High: $4.35

Volume

6,943,700 shs

Average Volume

6,844,139 shs

Market Capitalization

$555.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Bionano Genomics?

The following equities research analysts have issued reports on Bionano Genomics in the last year: BTIG Research, Oppenheimer Holdings Inc., and Scotiabank.
View the latest analyst ratings for BNGO.

What is the current price target for Bionano Genomics?

3 Wall Street analysts have set twelve-month price targets for Bionano Genomics in the last year. Their average twelve-month price target is $6.50, suggesting a possible upside of 247.6%. Oppenheimer Holdings Inc. has the highest price target set, predicting BNGO will reach $12.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $3.50 for Bionano Genomics in the next year.
View the latest price targets for BNGO.

What is the current consensus analyst rating for Bionano Genomics?

Bionano Genomics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BNGO will outperform the market and that investors should add to their positions of Bionano Genomics.
View the latest ratings for BNGO.

What other companies compete with Bionano Genomics?

Other companies that are similar to Bionano Genomics include Quanterix, Akoya Biosciences, Cue Health, Seer and Nautilus Biotechnology. Learn More about companies similar to Bionano Genomics.

How do I contact Bionano Genomics' investor relations team?

Bionano Genomics' physical mailing address is 9540 TOWNE CENTRE DRIVE SUITE 100, SAN DIEGO CA, 92121. The company's listed phone number is (858) 888-7600 and its investor relations email address is [email protected] The official website for Bionano Genomics is www.bionanogenomics.com. Learn More about contacing Bionano Genomics investor relations.